Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Jayanthi Srinivasiah"'
Autor:
Hatem Soliman, Varsha Shah, Gordan Srkalovic, Reshma Mahtani, Ellis Levine, Blanche Mavromatis, Jayanthi Srinivasiah, Mohamad Kassar, Robert Gabordi, Rubina Qamar, Sarah Untch, Heather M. Kling, Tina Treece, William Audeh
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background Increased usage of genomic risk assessment assays suggests increased reliance on data provided by these assays to guide therapy decisions. The current study aimed to assess the change in treatment decision and physician confidence
Externí odkaz:
https://doaj.org/article/87a37eaf5e5243ac9fe1d0dcb516b31f
Autor:
William Audeh, Varsha Shah, Rubina Qamar, Ellis G. Levine, Gordan Srkalovic, Reshma Mahtani, Sarah Untch, Heather M. Kling, Robert Gabordi, B Mavromatis, Tina Treece, Hatem Soliman, Mohamad Kassar, Jayanthi Srinivasiah
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
BMC Cancer
BMC Cancer
Background Increased usage of genomic risk assessment assays suggests increased reliance on data provided by these assays to guide therapy decisions. The current study aimed to assess the change in treatment decision and physician confidence based on
Autor:
Yuan Liu, Amelia Zelnak, William Jonas, Andrew Pippas, Ruth O'Regan, Mylin A. Torres, Petros Nikolinakos, Jayanthi Srinivasiah, Xiaoxian Li
Publikováno v:
Clinical Breast Cancer. 15:31-36
Background Neoadjuvant chemotherapy is widely used to downstage breast cancers before surgery and is an accepted standard of care among patients with early-stage breast cancer in whom adjuvant chemotherapy would be recommended. Pathologic complete re
Autor:
Aprille Belgrave, William G. Richards, Nancy M. Paris, James J. Burke, Sreekanth Reddy, Colleen Hope McDonough, Anand Jillella, Mark A. Taylor, Joni Short, Andrew William Pippas, Vamsi Kota, Howard A. Zaren, Guilherme Cantuaria, Melissa S. Dillmon, Geri Whitaker, Sharad A. Ghamande, Jayanthi Srinivasiah, Frederick M. Schnell, Andrew Emmons Green
Publikováno v:
Journal of Clinical Oncology. 36:e18651-e18651
e18651Background: Clinical trials promote excellence in cancer care but only 2 – 3 % of patients enroll on trials. 1Minorities who experience the greatest cancer burden are least likely to enroll, ...
Autor:
Christian Lytle, Marileila Varella-Garcia, Synthia Roherty, Jayanthi Srinivasiah, D Crenshaw, Robert Hromas, John Velasco, Kathleen E. Richkind
Publikováno v:
Cancer Genetics and Cytogenetics. 122:141-143
The AML1 gene, located at chromosome 21q22, encodes a component (CBFα2) of a heterodimeric transcription factor complex termed core binding factor (CBF), which binds to DNA and activates gene expression. Chromosomal rearrangements may lead to disrup
Autor:
Amy L. Adams, William Jonas, William C. Wood, Amelia Zelnak, Ruth O'Regan, Toncred M. Styblo, Fred Schnell, Rita Nahta, Sheryl G. A. Gabram, Jayanthi Srinivasiah, Monica Rizzo
Publikováno v:
Cancer Research. 72:2703-2703
Background: The addition of trastuzumab to preoperative chemotherapy for Her2-positive breast cancers has been shown to increase pCR rate, which correlates with improved outcome. The purpose of this study was to evaluate the efficacy of trastuzumab i
Autor:
R. C. Hermann, Jayanthi Srinivasiah, Harvey L. Bumpers, Monica Rizzo, F. M. Schnell, Seema Harichand-Herdt, Amelia Zelnak, Toncred M. Styblo, Ruth O'Regan, Sheryl G. A. Gabram
Publikováno v:
Journal of Clinical Oncology. 29:1118-1118
1118 Background: Achievement of pathologic complete response (pCR) to preoperative therapy is a predictor of improved disease-free and overall survival. Sequential and concurrent regimens of D and C were evaluated in patients with Her2-negative breas
Autor:
F. M. Schnell, Amelia Zelnak, Toncred M. Styblo, Monica Rizzo, S. Gabram-Mendola, W. S. Jonas, Brian Leyland-Jones, Jayanthi Srinivasiah, William C. Wood, Ruth O'Regan
Publikováno v:
Journal of Clinical Oncology. 28:625-625
625 Background: The addition of trastuzumab to preoperative chemotherapy for HER2-positive breast cancers has been shown to increase pCR rates. The purpose of this study was to evaluate the efficacy of trastuzumab in combination with dose-dense nab-p
Autor:
R. C. Hermann, Toncred M. Styblo, D Hicklin, K Carlson, Jayanthi Srinivasiah, Harvey L. Bumpers, N Sellers, Seema Harichand-Herdt, F. M. Schnell, Ruth O'Regan, Monica Rizzo, Amelia Zelnak, Carl J. D'Orsi, Sheryl G. A. Gabram, T Pierce, D Senior-Crosby
Publikováno v:
Cancer Research. 69:5122
Abstract #5122 Background The efficacy of D and C as single agents and in combination is well established in the treatment of metastatic breast cancer. Novel sequential and concurrent regimens of D and C were evaluated in patients with her2-negative